Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT02655757

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Li Bo (from the registry)
Registry
  • NCT NCT02655757
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02655757. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2017-02-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Sitagliptin on Progression of Coronary Intermediate Lesion
Condition
Atherosclerosis
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Lead sponsor
Li Bo (class: other)

Record details

Record id
cardio:ct-nct02655757
Content hash
3ddda7e8ef4b0502c8d8aa6a68462ced62ef9b02c79e1abfc766a46355e77404